Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Abstract

Background

Neuroprotection with cannabinoids in Parkinson’s disease (PD) has been afforded predominantly with antioxidant or anti-inflammatory cannabinoids. In the present study, we investigated the anti-inflammatory and neuroprotective properties of VCE-003.2, a quinone derivative of the non-psychotrophic phytocannabinoid cannabigerol (CBG), which may derive its activity at the peroxisome proliferator-activated receptor-γ (PPARγ). The compound is also an antioxidant.

Methods

We evaluated VCE-003.2 in an in vivo [mice subjected to unilateral intrastriatal injections of lipopolysaccharide (LPS)] model of PD, as well as in in vitro (LPS-exposed BV2 cells and M-213 cells treated with conditioned media generated from LPS-exposed BV2 cells) cellular models. The type of interaction of VCE-003.2 at the PPARγ receptor was furtherly investigated in bone marrow-derived human mesenchymal stem cells (MSCs) and sustained with transcriptional assays and in silico docking studies.

Results

VCE-003.2 has no activity at the cannabinoid receptors, a fact that we confirmed in this study using competition studies. The administration of VCE-003.2 to LPS-lesioned mice attenuated the loss of tyrosine hydroxylase (TH)-containing nigrostriatal neurons and, in particular, the intense microgliosis provoked by LPS in the substantia nigra, measured by Iba-1/Cd68 immunostaining. The analysis by qPCR of proinflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and inducible nitric oxide synthase (iNOS) in the striatum showed they were markedly elevated by the LPS lesion and strongly reduced by the treatment with VCE-003.2. The effects of VCE-003.2 in LPS-lesioned mice implied the activation of PPARγ receptors, as they were attenuated when VCE-003.2 was co-administered with the PPARγ inhibitor T0070907. We then moved to some in vitro approaches, first to confirm the anti-inflammatory profile of VCE-003.2 in cultured BV2 cells exposed to LPS. VCE-003.2 was able to attenuate the synthesis and release of TNF-α and IL-1β, as well as the induction of iNOS and cyclooxygenase-2 (COX-2) elicited by LPS in these cells. However, we found such effects were not reversed by GW9662, another classic PPARγ antagonist. Next, we investigated the neuroprotective effects of VCE-003.2 in cultured M-213 neuronal cells exposed to conditioned media generated from LPS-exposed cultured BV2 cells. VCE-003.2 reduced M-213 cell death, but again, such effects were not reversed by T0070907. Using docking analysis, we detected that VCE-003.2 binds both the canonical and the alternative binding sites in the PPARγ ligand-binding pocket (LBP). Functional assays further showed that T0070907 almost abolished PPARγ transcriptional activity induced by rosiglitazone (RGZ), but it did not affect the activity of VCE-003.2 in a Gal4-Luc system. However, T0070907 inhibited the effects of RGZ and VCE-003.2 on the expression of PPARγ-dependent genes upregulated in MSCs.

Conclusions

We have demonstrated that VCE-003.2 is neuroprotective against inflammation-driven neuronal damage in an in vivo model of PD and in in vitro cellular models of neuroinflammation. Such effects might involve PPARγ receptors, although in silico and in vitro experiments strongly suggest that VCE-003.2 targets PPARγ by acting through two binding sites at the LBP, one that is sensitive to T0070907 (canonical binding site) and other that is not affected by this PPARγ antagonist (alternative binding site).

Background

Inflammation is a key pathogenic event in Parkinson’s disease (PD), so that anti-inflammatory strategies are being investigated to limit neuronal deterioration in this disease [1]. Certain cannabinoids have proved important anti-inflammatory/neuroprotective properties, which have been primarily assigned to the role exerted by the cannabinoid receptor type-2 (CB2) in the control of glia-dependent inflammatory events typical of neurodegenerative/neuroinflammatory disorders [23]. However, its relevance in PD has remained elusive for years. A few years ago, Price and coworkers [4] described an elevation of CB2 receptors in microglial cells recruited at the lesion sites in mice intoxicated with MPTP, a model with a modest glial response. These authors found that targeting these receptors reduced the damage of nigrostriatal neurons [4], although a further study showed that the inhibition of microglial activation and the preservation of nigrostriatal dopaminergic neurons in MPTP-lesioned mice involved surprisingly the activation of the cannabinoid receptor type-1 (CB1) too [5]. In our laboratory, we worked with postmortem basal ganglia collected from PD patients and confirmed such upregulatory response of CB2 receptors in glial elements [6]. We also investigated the issue in an inflammatory model of nigrostriatal damage consisting in intrastriatal injection of lipopolysaccharide (LPS), in which we found elevated levels of CB2 receptors in the basal ganglia [67]. Such receptors may be apparently located in activated glial elements, although we did not investigate the cell substrates in which this response takes place. In addition, we found that CB2 receptor-deficient mice were more vulnerable to LPS lesion than wild-type animals [67], a difference that was not found in a model with poor inflammatory responses, mice lesioned with 6-hydroxydopamine, in which the death of dopaminergic neurons is related to mitochondrial dysfunction and oxidative damage [7]. In agreement with this difference, LPS-lesioned mice responded to compounds targeting the CB2 receptor by preserving tyrosine hydroxylase (TH)-containing neurons and by reducing microglial reactivity and macrophage infiltration [67]. In contrast, 6-hydroxydopamine-lesioned mice did not respond to CB2 receptor activation [8]. Such differences were recently confirmed by Concannon and coworkers [9] who compared the elevation of CB2 receptors in LPS-lesioned rats, which was paralleled by increased microglial activation, with the poor response found in rodents lesioned with 6-hydroxydopamine. However, work conducted by Ternianov and coworkers [10] supported a role of CB2 receptors in 6-hydroxydopamine-lesioned mice too, as they found that mice overexpressing CB2 receptors were more protected against 6-hydroxydopamine-induced nigrostriatal damage.

The anti-inflammatory potential of cannabinoids in PD has been recently reinforced with the possibility that some of them can also bind and activate specific receptor types of the peroxisome proliferator-activated receptor (PPAR) family such as PPARγ [1112]. Such nuclear receptors have long been involved in the control of neuroinflammatory responses [13], whereas specific non-cannabinoid PPARγ activators (e.g., thiazolidinediones) have been found to be active in experimental models of PD and have entered recently in clinical investigation [14]. Some endocannabinoids (e.g., anandamide and 2-arachidonoylglycerol) and their related signaling lipids (e.g., palmitoylethanolamide, oleylethanolamide), as well as different phytocannabinoids and their derivatives, have been found to exert PPARγ-mediated anti-inflammatory activity [121516]. We have recently designed, synthesized, and characterized different phytocannabinoid derivatives, in particular a series of quinone derivatives of cannabigerol (CBG) that behave as PPARγ activators [17,18,19], while retaining the lack of CB1/CB2 activity of their phytocannabinoid template. For this study, we were particularly interested in one non-thiophilic CBG quinone derivative, so-called VCE-003.2, whose ability to activate PPARγ [19] enables this compound to serve as an anti-inflammatory and a neuroprotectant in LPS-lesioned mice, the experimental model of PD that better reproduces inflammation as a pathogenic event in this disease. We have investigated VCE-003.2 in this in vivo PD model following previous research conducted in murine models of Huntington’s disease [19], which confirmed its activity at the PPARγ and its capability to cross the blood-brain barrier after systemic administration. In addition, we have extended this research with some in vitro experiments useful to confirm the anti-inflammatory profile of VCE-003.2 (cultured BV2 cells stimulated with LPS) or its neuroprotective effects (cultured M-213 neuronal cells incubated with conditioned media generated from cultured BV2 cells stimulated with LPS). In all these experimental approaches, the possible contribution of PPARγ activation has been investigated using selective inhibitors of these nuclear receptors. However, the lack of activity of classic PPARγ antagonists (e.g., T0070907, GW9662) against VCE-003.2 effects in the in vitro studies and the recent identification of a functional alternative binding site for PPARγ ligands that does not overlap with the canonical binding site used by glitazones [20] prompted us to investigate whether VCE-003.2 binds to this receptor at this different site using docking and transcriptional analyses. In an additional experiment presented as supplementary data (see Additional file 3), we have also investigated whether the cannabinoid receptor-independent antioxidant profile of VCE-003.2 enables this compound to also serve as neuroprotectant in 6-hydroxydopamine-lesioned mice, which is characterized, as mentioned above, by mitochondrial dysfunction and oxidative stress but having a poor inflammatory response. In this model, other antioxidant phytocannabinoids (Δ9-tetrahydrocannabinol, cannabidiol, Δ9-tetrahydrocannabivarin) have been shown to preserve nigrostriatal dopaminergic neurons by antioxidant mechanisms independent of cannabinoid receptors [7821]. With this study in whole, we expect to add experimental support to the idea that a pharmaceutical formulation, using a pleiotropic cannabinoid derivative targeting PPARγ receptors, and perhaps other relevant targets for PD, may be of great interest to reduce inflammation and oxidative stress, as well as to enhance neuronal integrity in PD.

Methods

Synthesis and receptor characterization of VCE-003.2

The quinone derivative of CBG (6-(3,7)-dimethyl-octa-2,6-dienyl)-5-hydroxy-3-pentyl-2-ethylamino-[1,4]benzoquinone), so-called VCE-003.2, was synthesized as described previously [19]. Its activity as a PPARγ activator was also previously characterized [19]. To confirm that, as expected, VCE-003.2 has no affinity at the CB1 and the CB2 receptors, we conducted radioligand binding assays using membranes purified from cells transfected with human CB1 or CB2 receptors (RBHCB1M400UA and RBXCB2M400UA; Perkin-Elmer Life and Analytical Sciences, Boston, MA, USA). The protein concentration was 8 μg/well for the CB1 receptor membranes and 4 μg/well for those of the CB2 receptor. The binding buffer was 50 mM Tris-Cl, 5 mM MgCl2, 2.5 mM EDTA, and 0.5 mg/mL bovine serum albumin (pH = 7.4) for CB1 and 50 mM TrisCl, 5 mM MgCl2, 2.5 mM EGTA, and 1 mg/mL bovine serum albumin (pH = 7.5) for CB2. The radioligand was [3H]-CP55940 (Perkin-Elmer) used at a concentration of membrane KD × 0.8 nM, and the final incubation volume was 200 μl for CB1 and 600 μl for CB2. Ninety-six-well plates and the tubes necessary for the experiment were previously siliconized with Sigmacote (Sigma-Aldrich, Madrid, Spain). Membranes were resuspended in the corresponding buffer and were incubated (90 min at 30 °C) with the radioligand and VCE-003.2 at a high concentration (40 μM) with the purpose to determine the percentage of radioligand displacement. Non-specific binding was determined with 10 μM WIN55212-2 and total radioligand binding by incubation with the membranes in absence of VCE-003.2. Filtration was performed by a Harvester® filtermate (Perkin-Elmer) with Filtermat A GF/C filters pretreated with polyethylenimine 0.05%. After filtering, the filter was washed nine times with a binding buffer and dried and a melt-on scintillation sheet (Meltilex™ A, Perkin-Elmer) was melted onto it. Then, radioactivity was quantified by a liquid scintillation spectrophotometer (Wallac MicroBeta Trilux, Perkin-Elmer). In the case of both CB1– and CB2-transfected membranes, radioligand displacement at these conditions was always lower than 50%, then indicating negligible activity at both cannabinoid receptor types with Ki values in the micromolar range (> 40 μM; data from at least 3 experiments performed in triplicate for each point).

Cultures of BV2 cells and M-213 neuronal cells

In a first experiment, mouse BV2 microglial cells (kindly provided by Dr. Carmen Guaza, Instituto Cajal, CSIC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, Madrid, Spain), 2 mM UltraGlutamine, and antibiotics (Lonza, Verviers, Belgium) in a humidified atmosphere of 5% CO2 at 37 °C. Cells were plated at a density of 45 × 104 cells per well in 12-well culture plates and incubated in DMEM with a reduction of FBS to 1%. Three hours later, cells were treated with 0.5 μg/ml LPS (from Escherichia coli 055:B5, Sigma-Aldrich, Madrid, Spain), alone or in combination with VCE-003.2, used at a concentration of 5 μM (selected from previous concentration–response studies), and added 1 h before LPS. Twenty hours after the addition of LPS, media were removed and used for the analysis of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels using commercial ELISA kits (ref. MTA00B, R&D Systems, Minneapolis, MN, USA for TNF-α, and ref. MLB00C, R&D Systems, Minneapolis, MN, USA for IL-1β), whereas cell pellets were collected for analyzing protein levels by the Lowry method, which were used to normalize the cytokine data. In a follow-up experiment, the procedure for cell plating, incubation, and treatment with LPS and VCE-003.2 described above was repeated again, but an additional experimental group consisting of cells treated with LPS (0.5 μg/ml), VCE-003.2 (5 μM), and GW9662 (10 μM; Abcam, Cambridge, UK) was added. Twenty hours after the addition of LPS, cell pellets were collected for the qPCR analysis of TNF-α, IL-1β, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2).

In a second experiment, cultured BV2 cells were maintained in DMEM (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, Madrid, Spain), 2 mM UltraGlutamine, and antibiotics (Lonza, Verviers, Belgium) in a humidified atmosphere of 5% CO2 at 37 °C. For experiments, cells were plated at a density of 2 × 105 cells per well in 6-well culture plates and incubated in DMEM with a reduction of FBS to 1%. Three hours later, cells were treated with 0.5 μg/ml LPS (from Escherichia coli 055:B5, Sigma-Aldrich, Madrid, Spain). Twenty-four hours after the addition of LPS, media were removed to be added to cultures of the rat M-213 striatal cell line (kindly provided by Dr. WJ Freed, National Institute on Drug Abuse, Bethesda, MD, USA) to induce cell death following a procedure described previously [22]. To this end, M-213 cells were maintained in DMEM supplemented with 10% FBS, 2 mM UltraGlutamine, and 1% antibiotics (Lonza, Verviers, Belgium) under a humidified 5% CO2 atmosphere at 37 °C. For cytotoxicity experiments, cells were seeded at 50,000 cells/well in 24-well plates and maintained under a humidified atmosphere (5% CO2) at 37 °C overnight. Afterwards, normal medium was completely replaced by the conditioned media generated in BV2 cell experiments, and then, M-213 cells were treated with the vehicle (0.1% DMSO) or with three different concentrations of VCE-003.2 (0.1, 0.5, and 1 μM; selected according to our previously published study [19], which described an IC50 = 1.2 μM for the binding of VCE003.2 to PPARγ receptors), added alone or combined with the selective PPARγ inhibitor T0070907 (10 μM; Cayman Chemical, Ann Arbor, Michigan, USA). Rosiglitazone (RGZ) (20 μM, according to [23] and laboratory experience; Sigma-Aldrich, Madrid, Spain) was also added, alone or combined with T0070907 (10 μM), as a positive control for PPARγ activation. Cells were incubated for 40 h before the neuronal death was analyzed with the MTT assay (Panreac AppliChem., Barcelona, Spain). The data were normalized in relation with a control group consisting in M-213 cells exposed to conditioned media generated by BV2 cells in absence of LPS.

Mesenchymal stem cell differentiation

Human mesenchymal stem cells (MSCs) derived from bone marrow were obtained as previously described [19]. Cells were seeded in α-MEM containing 15% FCS, 2 mM UltraGlutamine, 1 ng/ml bFGF, and antibiotics, and adipogenic differentiation was performed as described [19]. Treatment with RGZ (1 μM) and VCE-003.2 (1 μM) in the presence and the absence of T0070907 (5 μM) started at the same time as the differentiation process. After a week of differentiation, the mRNA expression for PPARγ isoform 2 (PPARγ2), lipoprotein-lipase (LPL), CCAAT/enhancer-binding protein-α (CEBPA), adiponectin (ADIPOQ), and fatty acid-binding protein 4 (FABP4) was analyzed as described [19].

PPARγ transcriptional assays

To analyze PPARγ transcriptional activity, HEK-293T cells were cultured in 24-well plates and transiently co-transfected with the expression vector GAL4-PPARγ and the luciferase reporter vectors GAL4-luc (firefly luciferase) and pRL-CMV (renilla luciferase) using Roti©-Fect (Carl Roth, Karlsruhe, Germany). After stimulation, the luciferase activities were quantified using Dual-Luciferase Assay (Promega, Madison, WI, USA).

Immunoblotting

Whole cell extracts were obtained by lysing the cells in NP-40 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 1% NP-40) supplemented with protease and phosphatase inhibitors. Lysate concentrations were determined by the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Proteins (30 μg/lane) were separated by SDS-PAGE, transferred onto PVDF membranes, and blocked with PBS-T (PBS + 0.1% Tween-20) containing 5% non-fat dry milk for 30 min at room temperature. Incubation with anti-PPARγ (ref. C26H12, Cell Signaling Technology, Beverly, MA, USA) and anti-α-actin (ref. AC-74, Sigma-Aldrich, Madrid, Spain) was performed overnight at 4 °C, and washed membranes were incubated with appropriate secondary antibodies coupled to horseradish peroxidase that were detected by an enhanced chemiluminescent reagent.

Animals and surgical lesions

Male C57BL/6 mice were housed in a room with a controlled photoperiod (06:00–18:00 light) and temperature (22 ± 1 °C). They had free access to standard food and water and were used at adult age (3- to 4-month-old; 25–30 g weight). All experiments were conducted according to European guidelines (directive 2010/63/EU) and approved by the “Comité de Experimentación Animal” of our university (ref. CEA-UCM 56/2012). For in vivo experiments, mice were anesthesized (ketamine 40 mg/kg + xylazine 4 mg/kg, i.p.) and subjected to unilateral injections of S. Minnesota LPS (Sigma-Aldrich, Madrid, Spain) into two points of the right striatum following the procedure developed by Hunter et al. [24]. We used the following stereotaxic coordinates from bregma: + 1.18 mm AP, − 1.5 mm ML, and − 3.5 mm DV, as well as − 0.34 mm AP, − 2.5 mm ML, and − 3.2 mm DV (see details in [24]). At each intrastriatal coordinate, 5 μg of LPS in a volume of 1 μl of saline was injected slowly (0.5 μl/30 s) and the needle was left in place for 5 min before being slowly withdrawn. This avoids generating reflux and a rapid increase in intracranial pressure. Controls were sham-operated and injected with 1 μl of saline using the same coordinates. After the application of LPS or saline, mice were also subjected to pharmacological treatments as described in the following section. The lesions were generated using unilateral administration, the advantage of which is that contralateral structures serve as controls for the different analyses.

Pharmacological treatments and sampling

LPS-lesioned mice were distributed in three groups and administered i.p. with 10 mg/kg of VCE-003.2, alone or in combination with 5 mg/kg of the PPARγ antagonist T0070907 (Cayman Chemical, Ann Arbor, Michigan, USA) [25] or vehicle [DMSO (3.3%) + Tween 20 (2%) + saline (94.7%)]. The experiment included a fourth group consisting of sham-operated mice also treated with DMSO-Tween 20-saline. The treatment was initiated approximately 16 h after the LPS lesion and was repeated daily for 21 days. One day after the last injection, mice were killed by rapid and careful decapitation and their brains were rapidly removed and frozen in 2-methylbutane cooled in dry ice and stored at − 80 °C for subsequent immunohistochemical analysis in the substantia nigra and qPCR analysis in the striatum.

Real-time qRT-PCR analysis

Brain coronal slices (around 500 μm thick) were made at levels containing the striatum, according to Palkovits and Brownstein Atlas [26]. Subsequently, such structure was dissected and used for qRT-PCR analysis. Cell pellets from the in vitro experiments were also used for qRT-PCR analysis. Total RNA was isolated from the different samples using SurePrep RNA/Protein Purification Kit (Fisher Bioreagents, Madrid, Spain). The total amount of RNA extracted was quantitated by spectrometry at 260 nm and its purity from the ratio between the absorbance values at 260 and 280 nm. After genomic DNA was removed (to eliminate DNA contamination), single-stranded complementary DNA was synthesized from up to 1 μg of total RNA using the commercial kits Rneasy Mini Quantitect Reverse Transcription (Qiazen, Hilgen, Germany) and iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The reaction mixture was kept frozen at − 20 °C until enzymatic amplification. Quantitative RT-PCR assays were performed using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) to quantify mRNA levels for TNF-α (ref. Mm99999068_m1), IL-1β (ref. Mm00434228_m1), iNOS (ref. Mm01309902_m1), and COX-2 (ref. Mm00478372_m1), using GAPDH expression (ref. Mm99999915_g1) as an endogenous control gene for normalization. The PCR assay was performed using the 7300 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), and the threshold cycle (Ct) was calculated by the instrument’s software (7300 Fast System, Applied Biosystems, Foster City, CA, USA). Expression levels were calculated using the 2−ΔΔCt method.

Immunohistochemical procedures

Brains were sliced in coronal sections (containing the substantia nigra) in a cryostat (30 μm thick) and collected on antifreeze solution (glycerol/ethylene glycol/PBS; 2:3:5) and stored at − 20 °C until used. Sections were mounted on gelatin-coated slides and, once adhered, washed in 0.1 M potassium PBS (KPBS) at pH 7.4. Then, endogenous peroxidase was blocked by 30-min incubation at room temperature in a peroxidaseblocking solution (Dako Cytomation, Glostrup, Denmark). After several washes with KPBS, sections were incubated overnight at room temperature with the following primary antibodies: (i) rabbit polyclonal anti-TH (Chemicon-Millipore, Temecula, CA, USA) used at 1/400; (ii) rabbit polyclonal anti-Iba-1 antibody (Wako Chemicals, Richmond, VA, USA) used at 1/300; or (iii) monoclonal rat anti-mouse Cd68 antibody (AbD Serotec, Oxford, UK) used at 1/200. Dilutions were carried out in KPBS containing 5% normal horse serum and 0.1% Triton X-100 (Sigma Chem., Madrid, Spain). After incubation, sections were washed in KPBS, followed by incubation with the corresponding biotinylated secondary antibody (1/400) (Vector Laboratories, Burlingame, CA, USA) for 1 h at room temperature. Avidin–biotin complex (Vector Laboratories, Burlingame, CA, USA) and 3,3′-diaminobenzidine substrate–chromogen system (Dako Cytomation, Glostrup, Denmark) were used to obtain a visible reaction product. Negative control sections were obtained using the same protocol with omission of the primary antibody. A Leica DMRB microscope and a DFC300FX camera (Leica, Wetzlar, Germany) were used for the observation and photography of the slides, respectively. For quantification of the intensity of TH, Iba-1, or CD68 immunostaining either in the substantia nigra (both ipsilateral and contralateral sides), we used the NIH Image Processing and Analysis software (ImageJ; NIH, Bethesda, MD, USA) using 4–5 sections, separated approximately by 200 μm, and observed with × 5–20 objectives depending on the method and the brain area under quantification. In all sections, the same area of the substantia nigra pars compacta was analyzed. Analyses were always conducted by experimenters who were blinded to all animal characteristics. Data were expressed as percentage of immunostaining intensity in the ipsilateral (lesioned) side over the contralateral (non-lesioned) side.

Immunofluorescence was used for a double-labeling analysis with TH and Cd68 in sections containing the substantia nigra pars compacta. After pre-incubation for 20 min with Tris-buffered saline with 1% Triton X-100 (pH 7.5), sections were sequentially incubated overnight at 4 °C with a monoclonal rat anti-mouse Cd68 antibody (AbD Serotec, Oxford, UK) used at 1/200, followed by washing in a Tris-buffered saline and a new incubation (at 37 °C for 2 h) with an anti-rat secondary antibody made in donkey (1/200) conjugated with Alexa 488 (Life Technologies-Thermofisher Scientific, Waltham, MA, USA) rendering green fluorescence. Sections were then washed again and incubated overnight at 4 °C with a polyclonal rabbit anti-TH (Chemicon-Merck Millipore, Darmstadt, Germany) used at 1/200, again followed by washing in a Tris-buffered saline and a new incubation (at 37 °C for 2 h) with an anti-rabbit secondary antibody made in goat (1/200) conjugated with Alexa 546 (Invitrogen, Carlsbad, CA, USA) rendering red fluorescence. Sections were counter-stained with nuclear stain TOPRO-3-iodide (Molecular Probes, Eugene, OR, USA) to visualize cell nuclei. A SP5 Leica confocal microscope was used for slide observation and photography.

Docking analysis

Ligand docking was performed using the AutoDock4 [27] and the Vina software [28] with the virtual screening tools PyRx [29] and PyMOL [30]. The receptor model used was the PDB reference (RCSB Protein Data Bank accession code) 2Q59 and 3B0R [20], and 4EMA [31]. The search space for the docking, around the receptor molecule surface, was set according to previous findings about several binding sites for different ligands. Once analysis has been performed, AutoDock Vina provides the estimated binding affinity value, which is the sum of the intermolecular energy, due to the interaction between both molecules, and the torsional free-energy penalty, due to the conformation adopted by these molecules to properly fit the interaction surface. A negative value indicates that the bond is thermodynamically stable, whereas a positive value means instability. Search space for the docking was set around the binding sites described previously [20].

Data analysis

Data were subjected to the one-way analysis of variance followed by the Student–Newman–Keuls, Tukey, or the Bonferroni multiple comparison tests.

 

https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1060-5

Leave a Reply
Easy 30 days returns

30 days money back guarantee

Quality Assurance

Offered in the country of usage

100% Secure Checkout

PayPal / MasterCard / Visa

© 2020 Vida Biologica. All Rights Reserved.